drugset / Trial / NCT03651518
Personalized Therapies in Inflammatory Complex Disease
Phase 2
Completed
32 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency
Timeline
- Start
- 2020-10-20
- Primary completion
- 2025-11-20
- Completion
- 2025-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | — |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Tocilizumab | Monoclonal antibody | 480 mg | Other |
| Subject | Ustekinumab | Monoclonal antibody | 45 mg | Subcutaneous |